A report about an extended-spectrum β-lactamase GES-1-producing P. aeruginosa, isolate 48-8896, which was recovered from a 63-yr-old female who had a hysterectomy (Sio Paulo, Brazil) and developed a wound infection while receiving ceftriaxone, amikacin, and metronidazole, and eventually died after being hospitalized in the intensive care unit for 3 mo.Isolate 48-8896 showed resistance to imipenem (MIC, >8 μg/mL), meropenem (MIC, >8 μg/mL), ceftazidime (MIC, >16 μg/mL), cefepime (MIC, >16 μg/mL), piperacillin-tazobactam (MIC, >64 μg/mL), and all antimicrobial agents evaluated (including aminoglycosides and quinolones), except for polymyxin B (MIC, <= 1 μg/mL).Phenotypic detection of ESBL was determined to be pos. using the (ceftazidime/ceftazidime-clavulanic acid and cefepime/cefepime-clavulanic acid) Etest strips (AB BIODISK, Solna, Sweden).We also looked into mutations in blaGES1 gene and class I integron containing blaGES1, possibly related to multi-drug resistance phenotype for this isolate.The detection of a GES-1-producing P. aeruginosa isolate in Latin America (Brazil) was a very worrisome finding, since it heralds the possibility for the emergence and future dissemination of new GES derivatives with broader spectra of hydrolyzes, such as the carbapenem-hydrolyzing enzyme GES-2.